nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0409	0.0546	CbGbCtD
Fesoterodine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0408	0.0544	CbGbCtD
Fesoterodine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0384	0.0513	CbGbCtD
Fesoterodine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0384	0.0513	CbGbCtD
Fesoterodine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0369	0.0492	CbGbCtD
Fesoterodine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0347	0.0464	CbGbCtD
Fesoterodine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0347	0.0464	CbGbCtD
Fesoterodine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0318	0.0425	CbGbCtD
Fesoterodine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0309	0.0413	CbGbCtD
Fesoterodine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.03	0.04	CbGbCtD
Fesoterodine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0291	0.0389	CbGbCtD
Fesoterodine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0279	0.0373	CbGbCtD
Fesoterodine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0279	0.0373	CbGbCtD
Fesoterodine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0268	0.0358	CbGbCtD
Fesoterodine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0263	0.0352	CbGbCtD
Fesoterodine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0263	0.0352	CbGbCtD
Fesoterodine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.026	0.0347	CbGbCtD
Fesoterodine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0244	0.0326	CbGbCtD
Fesoterodine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0244	0.0326	CbGbCtD
Fesoterodine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0221	0.0295	CbGbCtD
Fesoterodine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0221	0.0295	CbGbCtD
Fesoterodine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0207	0.0277	CbGbCtD
Fesoterodine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0191	0.0255	CbGbCtD
Fesoterodine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0185	0.0247	CbGbCtD
Fesoterodine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0167	0.0224	CbGbCtD
Fesoterodine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0167	0.0224	CbGbCtD
Fesoterodine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0161	0.0214	CbGbCtD
Fesoterodine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00106	0.0701	CbGeAlD
Fesoterodine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.00084	0.0555	CbGeAlD
Fesoterodine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000809	0.0534	CbGeAlD
Fesoterodine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000678	0.0448	CbGeAlD
Fesoterodine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000667	0.0441	CbGeAlD
Fesoterodine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000657	0.0433	CbGeAlD
Fesoterodine—CHRM4—brain—acquired immunodeficiency syndrome	0.000642	0.0424	CbGeAlD
Fesoterodine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000632	0.0417	CbGeAlD
Fesoterodine—CHRM5—brain—acquired immunodeficiency syndrome	0.000502	0.0331	CbGeAlD
Fesoterodine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00048	0.0317	CbGeAlD
Fesoterodine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000475	0.0313	CbGeAlD
Fesoterodine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000451	0.0298	CbGeAlD
Fesoterodine—CHRM1—lung—acquired immunodeficiency syndrome	0.000443	0.0292	CbGeAlD
Fesoterodine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000434	0.0286	CbGeAlD
Fesoterodine—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000429	0.0019	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000427	0.00189	CcSEcCtD
Fesoterodine—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000427	0.00189	CcSEcCtD
Fesoterodine—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000426	0.00189	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000426	0.00189	CcSEcCtD
Fesoterodine—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000425	0.00189	CcSEcCtD
Fesoterodine—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.000425	0.00188	CcSEcCtD
Fesoterodine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000425	0.00188	CcSEcCtD
Fesoterodine—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000423	0.00187	CcSEcCtD
Fesoterodine—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.000422	0.00187	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.00042	0.00186	CcSEcCtD
Fesoterodine—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.000419	0.00186	CcSEcCtD
Fesoterodine—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000418	0.00185	CcSEcCtD
Fesoterodine—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000417	0.00185	CcSEcCtD
Fesoterodine—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000415	0.00184	CcSEcCtD
Fesoterodine—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.000415	0.00184	CcSEcCtD
Fesoterodine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000415	0.00184	CcSEcCtD
Fesoterodine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000415	0.00184	CcSEcCtD
Fesoterodine—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000414	0.00183	CcSEcCtD
Fesoterodine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000413	0.00183	CcSEcCtD
Fesoterodine—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000413	0.00183	CcSEcCtD
Fesoterodine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000412	0.00183	CcSEcCtD
Fesoterodine—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.000412	0.00183	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000412	0.00183	CcSEcCtD
Fesoterodine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000412	0.00183	CcSEcCtD
Fesoterodine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000411	0.00182	CcSEcCtD
Fesoterodine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00041	0.0271	CbGeAlD
Fesoterodine—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00041	0.00182	CcSEcCtD
Fesoterodine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00041	0.00182	CcSEcCtD
Fesoterodine—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000409	0.00181	CcSEcCtD
Fesoterodine—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000409	0.00181	CcSEcCtD
Fesoterodine—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000408	0.00181	CcSEcCtD
Fesoterodine—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000407	0.0018	CcSEcCtD
Fesoterodine—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.000407	0.0018	CcSEcCtD
Fesoterodine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000407	0.0018	CcSEcCtD
Fesoterodine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000406	0.0018	CcSEcCtD
Fesoterodine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000406	0.0018	CcSEcCtD
Fesoterodine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000403	0.00178	CcSEcCtD
Fesoterodine—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000402	0.00178	CcSEcCtD
Fesoterodine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000401	0.00178	CcSEcCtD
Fesoterodine—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000399	0.00177	CcSEcCtD
Fesoterodine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000398	0.00176	CcSEcCtD
Fesoterodine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000397	0.00176	CcSEcCtD
Fesoterodine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000395	0.0261	CbGeAlD
Fesoterodine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000391	0.00173	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000391	0.00173	CcSEcCtD
Fesoterodine—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00039	0.00173	CcSEcCtD
Fesoterodine—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.00039	0.00173	CcSEcCtD
Fesoterodine—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00039	0.00173	CcSEcCtD
Fesoterodine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000388	0.00172	CcSEcCtD
Fesoterodine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000388	0.00172	CcSEcCtD
Fesoterodine—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000388	0.00172	CcSEcCtD
Fesoterodine—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000388	0.00172	CcSEcCtD
Fesoterodine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000387	0.00172	CcSEcCtD
Fesoterodine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000387	0.00172	CcSEcCtD
Fesoterodine—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000387	0.00171	CcSEcCtD
Fesoterodine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000385	0.00171	CcSEcCtD
Fesoterodine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000384	0.0017	CcSEcCtD
Fesoterodine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000384	0.0017	CcSEcCtD
Fesoterodine—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000383	0.0017	CcSEcCtD
Fesoterodine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000382	0.00169	CcSEcCtD
Fesoterodine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.00169	CcSEcCtD
Fesoterodine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000381	0.00169	CcSEcCtD
Fesoterodine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000378	0.00168	CcSEcCtD
Fesoterodine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000378	0.00168	CcSEcCtD
Fesoterodine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000378	0.00168	CcSEcCtD
Fesoterodine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000378	0.00168	CcSEcCtD
Fesoterodine—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000376	0.00167	CcSEcCtD
Fesoterodine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000376	0.00167	CcSEcCtD
Fesoterodine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000375	0.00166	CcSEcCtD
Fesoterodine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000374	0.00166	CcSEcCtD
Fesoterodine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000374	0.00166	CcSEcCtD
Fesoterodine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000373	0.00165	CcSEcCtD
Fesoterodine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000373	0.00165	CcSEcCtD
Fesoterodine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000372	0.00165	CcSEcCtD
Fesoterodine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000371	0.00164	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00037	0.00164	CcSEcCtD
Fesoterodine—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.00037	0.00164	CcSEcCtD
Fesoterodine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00037	0.00164	CcSEcCtD
Fesoterodine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000369	0.00164	CcSEcCtD
Fesoterodine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000369	0.00163	CcSEcCtD
Fesoterodine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000368	0.00163	CcSEcCtD
Fesoterodine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000367	0.00163	CcSEcCtD
Fesoterodine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000367	0.0242	CbGeAlD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000365	0.00162	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000364	0.00161	CcSEcCtD
Fesoterodine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000363	0.00161	CcSEcCtD
Fesoterodine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000363	0.00161	CcSEcCtD
Fesoterodine—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000362	0.00161	CcSEcCtD
Fesoterodine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000362	0.0016	CcSEcCtD
Fesoterodine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00036	0.0016	CcSEcCtD
Fesoterodine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00036	0.0016	CcSEcCtD
Fesoterodine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00036	0.00159	CcSEcCtD
Fesoterodine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000359	0.00159	CcSEcCtD
Fesoterodine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000358	0.00159	CcSEcCtD
Fesoterodine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000358	0.00158	CcSEcCtD
Fesoterodine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000356	0.00158	CcSEcCtD
Fesoterodine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000356	0.00158	CcSEcCtD
Fesoterodine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000356	0.00158	CcSEcCtD
Fesoterodine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000355	0.00157	CcSEcCtD
Fesoterodine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000354	0.00157	CcSEcCtD
Fesoterodine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000353	0.00157	CcSEcCtD
Fesoterodine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000353	0.0233	CbGeAlD
Fesoterodine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000351	0.00156	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000351	0.00156	CcSEcCtD
Fesoterodine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00035	0.00155	CcSEcCtD
Fesoterodine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000347	0.00154	CcSEcCtD
Fesoterodine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000346	0.00153	CcSEcCtD
Fesoterodine—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000346	0.00153	CcSEcCtD
Fesoterodine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000346	0.00153	CcSEcCtD
Fesoterodine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000345	0.00153	CcSEcCtD
Fesoterodine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000345	0.00153	CcSEcCtD
Fesoterodine—CHRM2—brain—acquired immunodeficiency syndrome	0.000344	0.0227	CbGeAlD
Fesoterodine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000344	0.00153	CcSEcCtD
Fesoterodine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000344	0.00153	CcSEcCtD
Fesoterodine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000344	0.00152	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000344	0.00152	CcSEcCtD
Fesoterodine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000343	0.00152	CcSEcCtD
Fesoterodine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000342	0.00152	CcSEcCtD
Fesoterodine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000342	0.00151	CcSEcCtD
Fesoterodine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00034	0.00151	CcSEcCtD
Fesoterodine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00034	0.00151	CcSEcCtD
Fesoterodine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00034	0.00151	CcSEcCtD
Fesoterodine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000339	0.0015	CcSEcCtD
Fesoterodine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000338	0.0015	CcSEcCtD
Fesoterodine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000338	0.0015	CcSEcCtD
Fesoterodine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000337	0.00149	CcSEcCtD
Fesoterodine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000337	0.00149	CcSEcCtD
Fesoterodine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000335	0.00149	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000335	0.00148	CcSEcCtD
Fesoterodine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000335	0.00148	CcSEcCtD
Fesoterodine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000333	0.00148	CcSEcCtD
Fesoterodine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000332	0.00147	CcSEcCtD
Fesoterodine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00033	0.00146	CcSEcCtD
Fesoterodine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00033	0.00146	CcSEcCtD
Fesoterodine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000329	0.00146	CcSEcCtD
Fesoterodine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000329	0.00146	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000329	0.00146	CcSEcCtD
Fesoterodine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000329	0.00146	CcSEcCtD
Fesoterodine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000328	0.00145	CcSEcCtD
Fesoterodine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000328	0.00145	CcSEcCtD
Fesoterodine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000328	0.00145	CcSEcCtD
Fesoterodine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000327	0.00145	CcSEcCtD
Fesoterodine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000326	0.00145	CcSEcCtD
Fesoterodine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000326	0.00144	CcSEcCtD
Fesoterodine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.00144	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000325	0.00144	CcSEcCtD
Fesoterodine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000325	0.00144	CcSEcCtD
Fesoterodine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000324	0.00143	CcSEcCtD
Fesoterodine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000323	0.00143	CcSEcCtD
Fesoterodine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000322	0.00143	CcSEcCtD
Fesoterodine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000321	0.00142	CcSEcCtD
Fesoterodine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000321	0.00142	CcSEcCtD
Fesoterodine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00032	0.00142	CcSEcCtD
Fesoterodine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000318	0.00141	CcSEcCtD
Fesoterodine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000317	0.00141	CcSEcCtD
Fesoterodine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000316	0.0014	CcSEcCtD
Fesoterodine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000315	0.00139	CcSEcCtD
Fesoterodine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000314	0.00139	CcSEcCtD
Fesoterodine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000314	0.00139	CcSEcCtD
Fesoterodine—CHRM1—brain—acquired immunodeficiency syndrome	0.000314	0.0207	CbGeAlD
Fesoterodine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000313	0.00139	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000311	0.00138	CcSEcCtD
Fesoterodine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00031	0.00138	CcSEcCtD
Fesoterodine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00031	0.00138	CcSEcCtD
Fesoterodine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.00137	CcSEcCtD
Fesoterodine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00031	0.00137	CcSEcCtD
Fesoterodine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000309	0.00137	CcSEcCtD
Fesoterodine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000306	0.00136	CcSEcCtD
Fesoterodine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000305	0.00135	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000304	0.00135	CcSEcCtD
Fesoterodine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000304	0.00135	CcSEcCtD
Fesoterodine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000302	0.00134	CcSEcCtD
Fesoterodine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000302	0.00134	CcSEcCtD
Fesoterodine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000301	0.00134	CcSEcCtD
Fesoterodine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000301	0.00133	CcSEcCtD
Fesoterodine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.00133	CcSEcCtD
Fesoterodine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000299	0.00133	CcSEcCtD
Fesoterodine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.00132	CcSEcCtD
Fesoterodine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000298	0.00132	CcSEcCtD
Fesoterodine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000293	0.0013	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.0013	CcSEcCtD
Fesoterodine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000292	0.0013	CcSEcCtD
Fesoterodine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000292	0.00129	CcSEcCtD
Fesoterodine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.00129	CcSEcCtD
Fesoterodine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.00128	CcSEcCtD
Fesoterodine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000288	0.00128	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.00128	CcSEcCtD
Fesoterodine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000287	0.00127	CcSEcCtD
Fesoterodine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000286	0.00127	CcSEcCtD
Fesoterodine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000285	0.00127	CcSEcCtD
Fesoterodine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000285	0.00126	CcSEcCtD
Fesoterodine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.00126	CcSEcCtD
Fesoterodine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000284	0.00126	CcSEcCtD
Fesoterodine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.00125	CcSEcCtD
Fesoterodine—CHRM3—brain—acquired immunodeficiency syndrome	0.000281	0.0185	CbGeAlD
Fesoterodine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000281	0.00124	CcSEcCtD
Fesoterodine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00028	0.00124	CcSEcCtD
Fesoterodine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.00124	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000279	0.00124	CcSEcCtD
Fesoterodine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000279	0.00124	CcSEcCtD
Fesoterodine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000279	0.00123	CcSEcCtD
Fesoterodine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.00123	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.00123	CcSEcCtD
Fesoterodine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.00123	CcSEcCtD
Fesoterodine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000273	0.00121	CcSEcCtD
Fesoterodine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000272	0.00121	CcSEcCtD
Fesoterodine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000269	0.00119	CcSEcCtD
Fesoterodine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000269	0.00119	CcSEcCtD
Fesoterodine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000269	0.00119	CcSEcCtD
Fesoterodine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.00119	CcSEcCtD
Fesoterodine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000266	0.00118	CcSEcCtD
Fesoterodine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000266	0.00118	CcSEcCtD
Fesoterodine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000265	0.00118	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.00117	CcSEcCtD
Fesoterodine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000264	0.00117	CcSEcCtD
Fesoterodine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000263	0.00117	CcSEcCtD
Fesoterodine—ABCB1—retina—acquired immunodeficiency syndrome	0.000263	0.0174	CbGeAlD
Fesoterodine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000261	0.0172	CbGeAlD
Fesoterodine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00026	0.00115	CcSEcCtD
Fesoterodine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000259	0.00115	CcSEcCtD
Fesoterodine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000257	0.00114	CcSEcCtD
Fesoterodine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000257	0.0169	CbGeAlD
Fesoterodine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.00113	CcSEcCtD
Fesoterodine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.00112	CcSEcCtD
Fesoterodine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000252	0.00112	CcSEcCtD
Fesoterodine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000251	0.00111	CcSEcCtD
Fesoterodine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000251	0.00111	CcSEcCtD
Fesoterodine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00025	0.00111	CcSEcCtD
Fesoterodine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.00111	CcSEcCtD
Fesoterodine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000249	0.0011	CcSEcCtD
Fesoterodine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000249	0.0011	CcSEcCtD
Fesoterodine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000248	0.0164	CbGeAlD
Fesoterodine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000245	0.0161	CbGeAlD
Fesoterodine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.00108	CcSEcCtD
Fesoterodine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000241	0.00107	CcSEcCtD
Fesoterodine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00024	0.00106	CcSEcCtD
Fesoterodine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00024	0.00106	CcSEcCtD
Fesoterodine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.00106	CcSEcCtD
Fesoterodine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000239	0.00106	CcSEcCtD
Fesoterodine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000238	0.00106	CcSEcCtD
Fesoterodine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.00105	CcSEcCtD
Fesoterodine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000233	0.00103	CcSEcCtD
Fesoterodine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000232	0.00103	CcSEcCtD
Fesoterodine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.00103	CcSEcCtD
Fesoterodine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.00101	CcSEcCtD
Fesoterodine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.001	CcSEcCtD
Fesoterodine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000224	0.000993	CcSEcCtD
Fesoterodine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.000984	CcSEcCtD
Fesoterodine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.000983	CcSEcCtD
Fesoterodine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.00098	CcSEcCtD
Fesoterodine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.000978	CcSEcCtD
Fesoterodine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.000947	CcSEcCtD
Fesoterodine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.000947	CcSEcCtD
Fesoterodine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.000946	CcSEcCtD
Fesoterodine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.000941	CcSEcCtD
Fesoterodine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.000927	CcSEcCtD
Fesoterodine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.000903	CcSEcCtD
Fesoterodine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.000903	CcSEcCtD
Fesoterodine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.000898	CcSEcCtD
Fesoterodine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000202	0.0133	CbGeAlD
Fesoterodine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.000892	CcSEcCtD
Fesoterodine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000199	0.0131	CbGeAlD
Fesoterodine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000194	0.0128	CbGeAlD
Fesoterodine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000851	CcSEcCtD
Fesoterodine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000191	0.0126	CbGeAlD
Fesoterodine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000187	0.0123	CbGeAlD
Fesoterodine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000185	0.0122	CbGeAlD
Fesoterodine—ABCB1—blood—acquired immunodeficiency syndrome	0.000176	0.0116	CbGeAlD
Fesoterodine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.00017	0.0112	CbGeAlD
Fesoterodine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000169	0.0112	CbGeAlD
Fesoterodine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000163	0.0108	CbGeAlD
Fesoterodine—ABCB1—lung—acquired immunodeficiency syndrome	0.000154	0.0102	CbGeAlD
Fesoterodine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000152	0.01	CbGeAlD
Fesoterodine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000143	0.00943	CbGeAlD
Fesoterodine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000137	0.00908	CbGeAlD
Fesoterodine—ABCB1—brain—acquired immunodeficiency syndrome	0.000109	0.00721	CbGeAlD
Fesoterodine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000105	0.00696	CbGeAlD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	4.66e-05	0.00452	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.62e-05	0.00448	CbGpPWpGaD
Fesoterodine—CHRM4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	4.56e-05	0.00442	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	4.54e-05	0.0044	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.43e-05	0.00429	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.43e-05	0.00429	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.43e-05	0.00429	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.42e-05	0.00428	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.38e-05	0.00425	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.37e-05	0.00424	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.37e-05	0.00423	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.33e-05	0.00419	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.29e-05	0.00416	CbGpPWpGaD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.24e-05	0.0041	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.2e-05	0.00407	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.18e-05	0.00406	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.17e-05	0.00404	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.15e-05	0.00402	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.14e-05	0.00402	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.11e-05	0.00399	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.11e-05	0.00398	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.06e-05	0.00393	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.03e-05	0.00391	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.03e-05	0.00391	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.03e-05	0.0039	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.94e-05	0.00382	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.86e-05	0.00374	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.86e-05	0.00374	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.86e-05	0.00374	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.84e-05	0.00372	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.8e-05	0.00368	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.78e-05	0.00367	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.77e-05	0.00365	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.75e-05	0.00363	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.68e-05	0.00356	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.63e-05	0.00352	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.57e-05	0.00346	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.57e-05	0.00346	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.56e-05	0.00345	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.56e-05	0.00345	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.56e-05	0.00345	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.52e-05	0.00341	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.52e-05	0.00341	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.47e-05	0.00337	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.41e-05	0.00331	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.37e-05	0.00327	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.2e-05	0.0031	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.19e-05	0.00309	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.16e-05	0.00306	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.07e-05	0.00297	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.04e-05	0.00294	CbGpPWpGaD
Fesoterodine—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	3.03e-05	0.00293	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.94e-05	0.00285	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.89e-05	0.0028	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.88e-05	0.00279	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.86e-05	0.00277	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.85e-05	0.00277	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.85e-05	0.00276	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.82e-05	0.00273	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.76e-05	0.00268	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	2.75e-05	0.00267	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.72e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.72e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.72e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.71e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.71e-05	0.00263	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.71e-05	0.00262	CbGpPWpGaD
Fesoterodine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	2.69e-05	0.00261	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.68e-05	0.0026	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.68e-05	0.0026	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.68e-05	0.0026	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.66e-05	0.00257	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.65e-05	0.00257	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.65e-05	0.00256	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.62e-05	0.00254	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.59e-05	0.00251	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.58e-05	0.0025	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.56e-05	0.00248	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.45e-05	0.00237	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.44e-05	0.00236	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.43e-05	0.00236	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.42e-05	0.00235	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.42e-05	0.00234	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.4e-05	0.00233	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.39e-05	0.00232	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.37e-05	0.0023	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	2.34e-05	0.00227	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.33e-05	0.00226	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.33e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.33e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.32e-05	0.00225	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.28e-05	0.00221	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.28e-05	0.00221	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.23e-05	0.00216	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.23e-05	0.00216	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.2e-05	0.00213	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.18e-05	0.00211	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.18e-05	0.00211	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.11e-05	0.00204	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.1e-05	0.00204	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.07e-05	0.002	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.07e-05	0.002	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.07e-05	0.002	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.06e-05	0.002	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.04e-05	0.00198	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.01e-05	0.00195	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.98e-05	0.00192	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.98e-05	0.00192	CbGpPWpGaD
Fesoterodine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.96e-05	0.0019	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.86e-05	0.00181	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.86e-05	0.0018	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.84e-05	0.00178	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.77e-05	0.00172	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.75e-05	0.00169	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.73e-05	0.00168	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.71e-05	0.00165	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.66e-05	0.00161	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.65e-05	0.00159	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.64e-05	0.00159	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.64e-05	0.00158	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.63e-05	0.00158	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.00158	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.00158	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.62e-05	0.00157	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.61e-05	0.00156	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.59e-05	0.00154	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.57e-05	0.00153	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.57e-05	0.00152	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.57e-05	0.00152	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.56e-05	0.00152	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.56e-05	0.00152	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.00151	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.55e-05	0.0015	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.55e-05	0.0015	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.55e-05	0.0015	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.54e-05	0.00149	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.54e-05	0.00149	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.00148	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.00148	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.52e-05	0.00147	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.52e-05	0.00147	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.00146	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.5e-05	0.00145	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.00144	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.48e-05	0.00144	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.48e-05	0.00144	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.48e-05	0.00143	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.46e-05	0.00142	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.44e-05	0.00139	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.43e-05	0.00139	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.42e-05	0.00137	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.42e-05	0.00137	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.41e-05	0.00137	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.4e-05	0.00136	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.4e-05	0.00136	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.4e-05	0.00135	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.4e-05	0.00135	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.39e-05	0.00135	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.39e-05	0.00135	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.38e-05	0.00133	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.38e-05	0.00133	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.38e-05	0.00133	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.00132	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.3e-05	0.00126	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.24e-05	0.00121	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.00118	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.22e-05	0.00118	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.18e-05	0.00115	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.17e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.17e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.17e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.00113	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.15e-05	0.00112	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.00112	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.00111	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.14e-05	0.0011	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.12e-05	0.00109	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.12e-05	0.00108	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.08e-05	0.00104	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.06e-05	0.00103	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.06e-05	0.00103	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.00102	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.00102	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.05e-05	0.00102	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.05e-05	0.00101	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.04e-05	0.00101	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.04e-05	0.00101	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.03e-05	0.001	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.69e-06	0.000939	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	9.67e-06	0.000937	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.66e-06	0.000936	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.57e-06	0.000927	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.56e-06	0.000926	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.53e-06	0.000924	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.44e-06	0.000915	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.3e-06	0.000901	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.16e-06	0.000887	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	9.15e-06	0.000886	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.02e-06	0.000874	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.9e-06	0.000863	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.77e-06	0.00085	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.77e-06	0.000849	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.74e-06	0.000847	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.65e-06	0.000838	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.64e-06	0.000837	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.38e-06	0.000812	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.24e-06	0.000799	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.24e-06	0.000799	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.21e-06	0.000796	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.21e-06	0.000796	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.19e-06	0.000794	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.13e-06	0.000788	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.13e-06	0.000788	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.02e-06	0.000777	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.85e-06	0.00076	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.5e-06	0.00063	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.27e-06	0.000608	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.25e-06	0.000606	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.19e-06	0.0006	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.18e-06	0.000598	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.16e-06	0.000596	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.1e-06	0.000591	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.08e-06	0.000589	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.06e-06	0.000588	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.01e-06	0.000582	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.65e-06	0.000547	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.63e-06	0.000546	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.58e-06	0.00054	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.52e-06	0.000535	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.51e-06	0.000534	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.45e-06	0.000528	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.84e-06	0.000469	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.82e-06	0.000467	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	4.8e-06	0.000465	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.63e-06	0.000449	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.61e-06	0.000447	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.26e-06	0.000316	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.25e-06	0.000315	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.25e-06	0.000315	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.24e-06	0.000314	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.22e-06	0.000312	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.21e-06	0.000311	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	3.04e-06	0.000295	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.87e-06	0.000278	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.84e-06	0.000276	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.72e-06	0.000264	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.92e-06	0.000186	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.91e-06	0.000185	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.89e-06	0.000183	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.88e-06	0.000182	CbGpPWpGaD
